Novartis, Servier team up on tumor-killing drug development

France's Servier has struck a deal with Novartis ($NVS) to develop oncology drugs that invade tumors and lead them to self-destruct. The two will team up on clinical candidates that inhibit the BCL-2 protein, which regulates programmed cell death. Under the agreement, the two will collaborate on finding a first indication for the in-development programs, dividing up commercial rights according to geography, Servier said. More